References
- Benson AB 3rd. New approaches to assessing and treating early-stage colon and rectal cancers: Cooperative group strategies for assessing optimal approaches in early-stage disease. Clin Cancer Res 2007; 13(22 Pt 2)6913s–6920s
- Kim GP, Erlichman C. Oxaliplatin in the treatment of colorectal cancer. Expert Opin Drug Metab Toxicol 2007; 3: 281–94
- Saif MW, Kang SP, Chu E. Treatment of metastatic colorectal cancer: From cytotoxic agents to molecular agents and multitargeted strategies. Oncology 2006; 20(14 Suppl 10)11–9
- Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25: 1539–44
- Hurwitz H, Saini S. Bevacizumab in the treatment of metastatic colorectal cancer: Safety profile and management of adverse events. Semin Oncol 2006; 33(5 Suppl 10)S26–S34
- Curtis BR, Kaliszewski J, Marques MB, Saif MW, Nabelle L, Blank J, et al. Immune-mediated thrombocytopenia resulting from sensitivity to oxaliplatin. Am J Hematol 2006; 81: 193–8
- Sørbye H, Bruserud Y, Dahl O. Oxaliplatin-induced haematological emergency with an immediate severe thrombocytopenia and haemolysis. Acta Oncol 2001; 40: 882–3
- Koutras AK, Makatsoris T, Paliogianni F, Kopsida G, Onyenadum A, Gogos CA, et al. Oxaliplatin-induced acute-onset thrombocytopenia, hemorrhage and hemolysis. Oncology 2004; 67: 179–82
- Buti S, Riccò M, Chiesa MD, Copercini B, Tomasello G, Brighenti M, et al. Oxaliplatin-induced hemolytic anemia during adjuvant treatment of a patient with colon cancer: A case report. Anticancer Drugs 2007; 18: 297–300
- Taleghani BM, Meyer O, Fontana S, Ahrens N, Novak U, Borner MM, et al. Oxaliplatin-induced immune pancytopenia. Transfusion 2005; 45: 704–8
- Desrame J, Broustet H, Darodes de Tailly P, Girard D, Saissy JM. Oxaliplatin-induced haemolytic anaemia. Lancet 1999; 354(9185)1179–80
- Garufi C, Vaglio S, Brienza S, Conti L, D'Attino RM, Girelli G, et al. Immunohemolytic anemia following oxaliplatin administration. Ann Oncol 2000; 11: 497
- Earle CC, Chen WY, Ryan DP, Mayer RJ. Oxaliplatin-induced Evan's syndrome. Br J Cancer 2001; 84: 441
- Chen VM, Thrift KM, Morel-Kopp MC, Jackson D, Ward CM, Flower RL. An immediate hemolytic reaction induced by repeated administration of oxaliplatin. Transfusion 2004; 44: 838–43
- Ulrich-Pur H, Penz M, Fiebiger WC, Schüll B, Kornek GV, Scheithauer W, et al. Oxaliplatin-induced fever and release of IL-6. Oncology 2000; 59: 187–9
- Tonini G, Santini D, Vincenzi B, Borzomati D, Dicuonzo G, La Cesa A, et al. Oxaliplatin may induce cytokine-release syndrome in colorectal cancer patients. J Biol Regul Homeost Agents 2002; 16: 105–9
- Lim KH, Huang MJ, Lin HC, Su YW, Chang YF, Lin J, et al. Hypersensitivity reactions to oxaliplatin: A case report and the success of a continuous infusional desensitization schedule. Anticancer Drugs 2004; 15: 605–7
- Edmondson DA, Gruling BJ, Urmanski AM, Wong SJ, Levy MB. Oxaliplatin hypersensitivity: Case report and successful repeat desensitization. Am J Ther 2007; 14: 116–8